ClinicalTrials.gg
RecruitingNCT04038502COBRAUpdated Nov 16, 2026

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

A Phase 2 interventional study of Carboplatin and Olaparib in Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2 and RAD51B, RAD51C, RAD51D, or RAD54L Mutations, sponsored by VA Office of Research and Development. Recruiting at 18 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by VA Office of Research and Development · Phase 2, Interventional, and Health services research

How we know · 5 judgments

From the registry’s dates

  • Started Oct 2019; still recruiting 7 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies in Fanconi Anemia, Complementation Group D1 with a site in United States — 3 open to participants now, 5 under way, none of them phase 3. Fanconi Anemia, Complementation Group D1 · United States.

Planned enrollment
10th of 15
100 · median 114
Started
2019
the only one that year
Phase 2
8 of 19
2 open now
Registered
16th of 19
by date

Among the 19 studies in Fanconi Anemia, Complementation Group D1 with a site in United States, this one is the 10th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2019, is one of 8 in phase 2, and was the 16th registered.

Fanconi Anemia, Complementation Group D1

33 studies on the registry are indexed under Fanconi Anemia, Complementation Group D1; 4 are open to participants now.

Browse Fanconi Anemia, Complementation Group D1 studies →

Open to participants now

3 of the 19 studies in Fanconi Anemia, Complementation Group D1 with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Fanconi Anemia, Complementation Group D1 studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Fanconi Anemia, Complementation Group D1 with a site in United States, or all of them as a file.
02

Study summary

This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations.

Participants are randomized (1:1) and receive either carboplatin (AUC 5, IV) every 21 days, first or olaparib taken orally (300 mg), twice daily in 28 day cycles, until intolerance, complete response, or progression by Prostate Cancer Working Group 3 (PCWG3) criteria.

Participants then crossover from the first-line therapy to the second-line therapy with the opposite study medication and receive treatment to intolerance or progression (whichever is first). Enrolled participants will be allowed to crossover to second line therapy if they continue to meet initial eligibility criteria, and at least three weeks have elapsed since last administration of either carboplatin or olaparib. Throughout the study, safety and tolerability will be assessed. Progression will be evaluated with bone scan, CT of the abdomen/pelvis, or MRI and PSA as per PCWG3 criteria.

Read the detailed description

Study General Trial Over-view

This study is designed to help better understand treatment options compared to standard therapies for patients who have targeted DNA repair mutations and metastatic castrate resistant prostate cancer (mCRPC).

Cancer therapies are aimed at finding a way to kill the cancer cells while causing minimal damage to normal (non-cancer) cells. This often works because cancers cells grow faster than many normal cells, many treatments are aimed at to take advantage of that difference. One of the ways to do this is to damage the DNA of these more rapidly growing cells. However, if the cells have a way of repairing that damage then therapies may not work as well. Some research shows that when specific changes or mutations occur in the genes involved with repairing DNA damage, resulting cancers have responded well to drugs which damage DNA.

Olaparib is known as a PARP inhibitor and is standard of care therapy for men with BRCA altered mCRPC. Carboplatin is a synthetic antineoplastic agent which has been used in the treatment of solid tumors and BRCA related cancers. When mutations occur in critical DNA-repair genes, research has found that treatment with carboplatin is also effective.

This research is being done to determine the response of mCRPC in patients with DNA repair mutations to treatment with olaparib compared to carboplatin. This study will test whether giving one drug or the other a has a better response.

Patients wishing to participate in this study are screened for safety and health eligibility before enrolling.

This study is enrolling 100 male participants total, from across the VAMC nationally who have the following:

  • Metastatic castration-resistant prostate cancer (mCRPC)
  • Cancer that has gotten worse, after any number of first-line treatments
  • Mutations in DNA-repair genes discovered as part of a patient's routine care.

Once eligibility is determined, enrolled participants are randomized into one of two groups:

  • Group A will start with carboplatin (IV) first, given every 21 days, then have the option to switch to the second treatment with olaparib taken daily, (orally) with cycles of every 28 days.
  • Group B will start with olaparib first, taken (orally), with 28 day cycles, then have the option to switch to the second treatment with carboplatin (IV) every 21 days.

Both study drugs in this trial are currently FDA approved, and are prescribed at the participating VAMC clinical sites per institutional guidelines. Carboplatin given in IV is also given as prescribed at the participating VAMC, and administered per institutional guidelines.

Participants are monitored for health and body function, cancer progression, toxicity and life quality at every visit during the trial and at an end of treatment visit (28 days after completion of the trial or after withdrawal). For participants who respond well to treatment during the trial, additional treatment cycles may be added and the study can be extended. Participants who experience intolerable toxicity, cancer progression, or whose doctors decide to change treatment, will either be switched to the opposite study drug or withdrawn from the study.

This important trial is designed to compare response rate and duration of response using carboplatin compared to olaparib in patients who have mCRPC which contains DNA repair gene mutations.

03

Conditions studied

  • Metastatic Castrate Resistant Prostate Cancer
  • BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2
  • RAD51B, RAD51C, RAD51D, or RAD54L Mutations

Keywords

  • metastatic prostate cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed study form (ICF) and HIPAA authorization form
  2. Diagnosis of prostate cancer (pure small-cell histology or pure high-grade neuroendocrine histology are excluded; neuroendocrine differentiation is allowed)
  3. Ongoing gonadal androgen deprivation therapy with gonadotropin-releasing hormone (GnRH) analogues, antagonists or orchiectomy. Patients who have not had an orchiectomy must be maintained on effective GnRH analogue/antagonist therapy
  4. mCRPC as defined by serum testosterone \< 50 nanograms per milliliter (ng/ml) for patients on GnRH analogues or antagonists) and at least one of the following:

    • Prostate-specific antigen (PSA) level of at least 2 nanograms per milliliter (ng/ml) that has risen on at least 2 successive occasions at least 1 week apart
    • Evaluable disease progression by modified 1.1 (Response Evaluation Criteria in Solid Tumors)
    • Progression of bone disease on bone scan, CT or MRI with > 2 new lesions
  5. Prior therapy with abiraterone acetate, enzalutamide, apalutamide, or darolutamide
  6. (ECOG) Performance Status of \< 2 (see Appendix 3, ECOG Grading Scale)
  7. Results of previous standard DNA testing, or previous research testing, which confirms RAD51B, RAD51C, RAD51D, or RAD54L mutations (see Introduction, Section 2 for study design and previous research on targeted therapy) from primary, metastatic tumor or circulating tumor DNA, or pathogenic/likely pathogenic germline variant as assessed by a CLIA certified laboratory level assay for DNA sequencing.
  8. Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below:

    • > 10.0 grams per deciliter (g/dL)
    • (ANC) > 1.5 x 109/liter (L)
    • count > 100 x 109/L
    • Total \< 1.5 x institutional (ULN)
    • (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT) \< 2.5 x institutional upper limit of normal unless liver metastases are present in which case, they must be \< 5x ULN
    • Patients must have estimated using the Cockcroft-Gault equation of >51 mL/min: Estimated creatinine clearance =(140-age [years]) x weight (kg)/(serum creatinine (mg/dL) x 72)

Exclusion criteria

Exclusion Criteria:

  1. Currently receiving active therapy for other neoplastic disorder(s)
  2. Concurrent enrollment in another clinical drug or device study
  3. Histologic evidence of small cell carcinoma (morphology alone - immunohistochemical evidence of neuroendocrine differentiation without morphologic evidence is not exclusionary)
  4. Prior treatment with platinum, mitoxantrone or PARP inhibitor for castration resistant prostate cancer
  5. Known parenchymal
  6. Active or symptomatic viral hepatitis or chronic liver disease or ALT > 2.5 x or total > ULN (unless Gilbert's syndrome is the etiology of hyperbilirubinemia)
  7. Subjects with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of MDS/AML
  8. Concomitant use of known strong inhibitors (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required prior to starting olaparib is 2 weeks
  9. Concomitant use of known strong (e.g. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (e.g. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for phenobarbital and 3 weeks for other agents
  10. Subjects unable to swallow orally administered medication and subjects with gastrointestinal disorders likely to interfere with absorption of the study medication
  11. heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or (NYHA) Class II-IV heart disease or cardiac measurement of \< 35 % at baseline
  12. Treatment with an investigational therapeutic within 30 days of Cycle-1
  13. Presence of dementia, psychiatric illness, and/or social situations limiting compliance with study requirements or understanding HIPAA authorization and/or giving of
  14. Any condition(s), medical or otherwise, which, in the opinion of the Investigators, would jeopardize either the patient or the integrity of the data obtained
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Treatment Arm 1 - Carboplatin to Olaparib

    Participants are administered carboplatin AUC 5 IV first, which is administered Cycle-1, Day-1, and then every 21 days as first line therapy. For second line (crossover), olaparib is prescribed and taken orally at home, twice daily, 300 mg in 28 day cycles.

    Drug: Carboplatin · Drug: Olaparib

  • Active comparator
    Treatment Arm 2 - Olaparib to Carboplatin

    Participants are prescribed olaparib which is taken orally at home, twice daily, 300 mg in 28 day cycles, as first line therapy. For second line (crossover), carboplatin is administered AUC 5 IV every 21 days thereafter.

    Drug: Carboplatin · Drug: Olaparib

Interventions

  • Chemotherapy FDA approved drug used to treat: ovarian, lung, head and neck cancers. It is sometimes used in combination with other medications or off-label use to treat other metastatic cancers.

    Also known as: Paraplatin

  • Olaparib is a targeted therapy drug that is used for mCRPC and is approved by the FDA for this use.

    Also known as: Lynparza

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS-1L) defined as the time interval between randomization and first documented disease progression or death due to any cause reported during, or after, first-line treatment

    Progression free survival (PFS) by bone scan or measurable disease, Response Evaluation Criteria in Solid Tumors (RECIST 1.1) to initial therapy (PFS-1L) with either study drug

    Time frame: Through duration of the study, up to 100 weeks

Secondary outcomes

  1. Time interval between randomization and second documented disease progression during or after second-line or death (due to any cause)

    Progression-free survival combined, a composite endpoint defined as the time interval between randomization and second documented disease progression reported during or after second-line or death due to any cause

    Time frame: Through duration of the study, up to 100 weeks

  2. PSA measurements/response

    To assess PSA response to initial therapy with carboplatin vs. olaparib

    Time frame: Through duration of the study, up to 100 weeks

  3. PSA measurements/response

    To assess PSA response duration to second line therapy with olaparib vs carboplatin

    Time frame: Through duration of the study, up to 100 weeks

  4. Grade 3 and 4 toxicities in first and second-line setting

    To assess Grade 3 and 4 toxicities for each regimen in the first- and second-line setting

    Time frame: Through duration of the study, up to 100 weeks

  5. To assess cost effectiveness of carboplatin versus olaparib for the treatment of castration-resistant metastatic prostate cancer

    To assess cost effectiveness of carboplatin versus olaparib for the treatment of castration-resistant metastatic prostate cancer

    Time frame: Through duration of the study, up to 100 weeks

Other outcomes

  1. Exploratory Objective - PFS

    To assess the PFS of patients who receive olaparib versus patients who receive carboplatin during the second-line of treatment (PFS-2L)

    Time frame: Through duration of the study, up to 100 weeks

  2. Exploratory Objective - objective response rate

    To assess the objective response rate in patients who receive olaparib versus patients who receive carboplatin during second-line of treatment.

    Time frame: Through duration of the study, up to 100 weeks

  3. Exploratory Objective- objective duration of response

    To assess the objective duration of response in patients who receive olaparib versus patients who receive carboplatin during second-line of treatment.

    Time frame: Through duration of the study, up to 100 weeks

07

Study locations

15 of 18 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2019 (actual). Primary completion is estimated for Aug 2027, 94 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2019
First posted
Jul 30, 2019
StartActual
Oct 1, 2019
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers
1 update, last Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Minor edits only
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04038502
Responsible party
Sponsor
First posted
Jul 30, 2019
Start date
Oct 1, 2019
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Robert B Montgomery, MD
Contact
Robert.Montgomery@va.gov
(206) 277-6878
Makayla L DeJong, BA
Contact
Makayla.Dejong@va.gov
(206) 277-4527
Robert B. Montgomery, MD
principal investigator · VA Puget Sound Health Care System Seattle Division, Seattle, WA
Ryan Burri, MD
principal investigator · Bay Pines VA Healthcare System, Pay Pines, FL
Phoebe Tsao, MD MSc
principal investigator · VA Ann Arbor Healthcare System, Ann Arbor, MI
Maneesh Jain, MD
principal investigator · Washington DC VA Medical Center, Washington, DC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carboplatin · Olaparib

Start the discussion